Some suggested mechanisms for the synergy of the combinations in enhancing the response and preventing the relapse are the upregulation by inhibitors of histone deacetylases of CD80 and CD86 in the context of anti-CTLA-4 treatment, the regulation of immune checkpoint ligands, and the induction of tumor neoantigens on tumor cells for PD-1/PD-L1 therapy. This evidence concerns the gene CD80 and neoplasm.